Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma Verified

What's the purpose of this trial?

The goal of this clinical trial is to determine if carfilzomib, lenalidomide and dexamethasone are safe and effective in treating high-risk smoldering multiple myeloma.

This trial is currently open and accepting patients.


What's being studied?

  • Carfilzomib is a proteasome inhibitor that interferes with the growth and spread of cancer cells in the body.
  • Dexamethasone is a steroid given in conjunction with some cancer treatments that also has anti-cancer activity.
  • Lenalidomide is an immunomodulatory drug that helps your body fight cancer by stimulating antibody formation and also by slowing tumor growth.

What will happen during the trial?

This study is organized into 28 day cycles, with patients scheduled to receive:

  • Carfilzomib, by intravenous infusion, on days 1, 2, 8, 9, 15, 16
  • Lenalidomide, taken orally on days 1-21
  • Dexamethasone, taken orally on days 1, 2, 8, 9, 15, 16, 22, 23

After the first 4 cycles (approximately 4 months), stem cell transplant eligible patients may decide to have their stem cells collected and stored. After the initial 8 cycles (approximately 8 months), patients whose smoldering myeloma has not gotten worse may have up to 12 additional cycles of oral lenalidomide alone.


Additional Trial Information

Phase 2

Enrollment: 40 patients (estimated)

View More

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.

View Additional Criteria

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Maryland

National Institutes of Health (NIH)

Bethesda, MD

Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with National Cancer Institute (NCI) to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors